GE Healthcare Ireland Limited is recalling approximately 1,173,380 vials of Omnipaque (iohexol) Injection, a contrast agent used in medical imaging, due to the presence of particulate matter in certain batches. Using an injectable medication containing foreign particles can lead to serious health complications, such as blood clots or inflammation. No injuries have been reported to date, but the company has initiated this voluntary recall for 29 specific lots distributed nationwide to hospitals and clinics.
The presence of particulate matter in an injectable drug can cause local irritation, inflammation, or the blockage of blood vessels, which could lead to serious medical events like a stroke or pulmonary embolism. If you have received this injection and have health concerns, contact your healthcare provider immediately.
Distributed by: GE Healthcare Inc., Marlborough, MA 01752 USA. Total quantity: 866,570 vials.
Distributed by: GE Healthcare Inc., Marlborough, MA 01752 USA. Total quantity: 306,810 vials.
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.